Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical Technology Enterprise Consortium, 55204-55205 [2018-23989]

Download as PDF 55204 Federal Register / Vol. 83, No. 213 / Friday, November 2, 2018 / Notices Tomasetti, Inc., Washington, DC; Toyon Research Corporation, Goleta, CA; Transtecs Corporation, Arlington, VA; Triton Systems, Inc., Chelmsford, MA; Ultra Electronics Ocean Systems, Inc., Braintree, MA; UnderSea Sensor Systems, Inc. (USSI), Columbia City, IN; University of Florida Board of Trustees, Gainesville, FL; University of Rhode Island, Kingston, RI; Viasat, Inc., Carlsbad, CA; Visionary Products, Inc. (dba VPI Technology Group), Draper, UT; Welkins LLC, Downers Grove, IL; Woods Hole Oceanographic Institution, Woods Hole, MA; and World Wide Technology, Maryland Heights, MO. The general area of UTIC’s planned activity is conducting research, development and testing in cooperation with the Government leading to technology demonstrations in undersea and maritime technology applications and solutions through the following technology areas: Sensors and Sonar; Platform and Payload Integration; Undersea Distributed Networked Systems; Electronics/Optics/Materials; Passive Sensing; Undersea Satellites; Energy Storage and Release; Virtualization; Machine Learning; Threat Monitoring and Prediction; Cooperative Force Torpedo Defense; Undersea Warfare Analysis; MultiDomain Fusion; Electronic Warfare; Distributed and Autonomous Sensors; USW Weapons and Autonomous Vehicles; Autonomy; Quantum Computing; Bio-Inspired Sensors; Environmental Sensing, Monitoring and Prediction; In-Situ Energy Sources; and Multi-Dimensional Display. Suzanne Morris, Chief, Premerger and Division Statistics Unit Antitrust Division. [FR Doc. 2018–23984 Filed 11–1–18; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group on Corrosion Under Insulation Notice is hereby given that, on October 4, 2018, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Southwest Research Institute— Cooperative Research Group on Cooperative Research Group on Corrosion Under Insulation (‘‘CUI–JIP’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade VerDate Sep<11>2014 17:57 Nov 01, 2018 Jkt 247001 Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, The Dow Chemical Company, Freeport, TX, has been added as a party to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and CUI–JIP intends to file additional written notifications disclosing all changes in membership. On March 22, 2018, CUI–JIP filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on April 24, 2018 (83 FR 17851). The last notification was filed with the Department on September 6, 2018. A notice was published in the Federal Register pursuant to section 6(b) of the Act on September 17, 2018 (83 FR 46972). Suzanne Morris, Chief, Premerger and Division Statistics Unit, Antitrust Division. [FR Doc. 2018–23988 Filed 11–1–18; 8:45 am] activity of the group research project. Membership in this group research project remains open, and RIC-Americas intends to file additional written notifications disclosing all changes in membership. On April 30, 2014, RIC-Americas filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on June 9, 2014 (79 FR 32999). The last notification was filed with the Department on August 17, 2018. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on September 4, 2018 (83 FR 44904). Suzanne Morris, Chief, Premerger and Division Statistics Unit, Antitrust Division. [FR Doc. 2018–23983 Filed 11–1–18; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical Technology Enterprise Consortium BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group on ROS-Industrial ConsortiumAmericas Notice is hereby given that on September 28, 2018, Pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Southwest Research Institute— Cooperative Research Group on ROSIndustrial Consortium-Americas (‘‘RICAmericas’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Stratasys, Inc., Eden Prairie, MN, and Cognex Corporation, Natick, MA, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 Notice is hereby given that, on October 12, 2018, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Medical Technology Enterprise Consortium (‘‘MTEC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, 8i Labs, Inc., Los Angeles, CA; Adaptive Phage Therapeutics, Inc. (Aphage), Gaithersburg, MD; Aleo BME, Inc., State College, PA; American Defense International (ADI), Washington, DC; Aptima, Inc., Woburn, MA; Atlantic Diving Supply, Inc. (ADS), Virginia Beach, VA; Benchmark Electronics, Inc., Scottsdale, AZ; BioMojo LLC, Cary, NC; BioSpyder Technologies, Inc., Carlsbad, CA; Brain Mapping Foundation, West Hollywood, CA; Brain Power, LLC, Cambridge, MA; BrainScope Company, Inc., Bethesda, MD; CAE Healthcare, Inc., Sarasota, FL; Carmell Therapeutics Corporation, Pittsburgh, PA; Case Western Reserve University, Cleveland, OH; Cell Guidance Systems Ltd., E:\FR\FM\02NON1.SGM 02NON1 55205 Federal Register / Vol. 83, No. 213 / Friday, November 2, 2018 / Notices Cambridge, UK; Clear Scientific, LLC, Cambridge, MA; Cornerstone Government Affairs, Inc., Washington, DC; DePuy Synthes Products, Inc., Raynham, MA; Dignitas Technologies, Orlando, FL; ECM Therapeutics, Inc., Warrendale, PA; ElMindA Ltd., Herzliya, Israel; Family Health International DBA FHI 360, Durham, NC; Hypatia Project, Reston, VA; Institutes for Behavior Resources, Inc. (IBR), Baltimore, MD; Integrated MicroSciences, LLC, Frederick, MD; J. Craig Venter Institute (JCVI), Rockville, MD; KaloCyte, Inc., St. Louis, MO; Lieber Institute, Inc., Baltimore, MD; NanoDirect, LLC, Baltimore, MD; OXYVITA, Inc., Middletown, NY; Parsons Government Services, Inc., Pasadena, CA; Protocentral, Inc., Woburn, MA; Q2Pharma, Haifa, Israel; RAIN Scientific, Inc., Asheville, NC; Rehat, LLC, Pittsburgh, PA; Research Foundation for Mental Hygiene, Inc. (NYSPI), New York, NY; Responde2 Corporation, Mountain View, CA; Saint Barnabas Medical Center (SBMC), Livingston, NJ; San Diego Blood Bank, San Diego, CA; SmartMD Systems, Inc., Manchester Center, VT; Sonica LLC, Evanston, IL; Spire, San Francisco, CA; Syracuse University, Syracuse, NY; The Charles Stark Draper Laboratory, Inc. (Draper), Cambridge, MA; The University of Arizona, Defense and Security Research Institute (DSRI), Tucson, AZ; Trauma Insight, LLC, San Antonio, TX; Trustees of Boston University, Boston, MA; University of Central Florida Research Foundation, Inc., Orlando, FL; University of Houston—Cullen College of Engineering, Houston, TX; Vivonics, Inc., Bedford, MA; and Washington State University, Pullman, WA; have been added as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MTEC intends to file additional written notifications disclosing all changes in membership. On May 9, 2014, MTEC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on June 9, 2014 (79 FR 32999). The last notification was filed with the Department on May 3, 2018. A notice was published in the Federal VerDate Sep<11>2014 17:57 Nov 01, 2018 Jkt 247001 Register pursuant to Section 6(b) of the Act on June 19, 2018 (83 FR 28448). Suzanne Morris, Chief, Premerger and Division Statistics Unit Antitrust Division. Dated: October 24, 2018. John J. Martin, Assistant Administrator. [FR Doc. 2018–24005 Filed 11–1–18; 8:45 am] BILLING CODE 4410–09–P [FR Doc. 2018–23989 Filed 11–1–18; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Drug Enforcement Administration DEPARTMENT OF JUSTICE [Docket No. DEA–392] Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Registration ACTION: The registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of various classes of schedule I and II controlled substances. SUMMARY: The companies listed below applied to be registered as bulk manufacturers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices. SUPPLEMENTARY INFORMATION: FR citation Chemtos, 83 FR 37520 LLC. Johnson 83 FR 34880 Matthey Inc. AMRI 83 FR 38179 Rensselaer, Inc. Published August 1, 2018. July 23, 2018. August 3, 2018. The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of these registrants to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed companies. PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 2, 2019. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. DATES: Notice of registration. Company Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals, Inc. The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on September 13, 2018, Janssen Pharmaceuticals, Inc., Buildings 1–5 & 7–14, 1440 Olympic Drive, Athens, Georgia 30601 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: SUPPLEMENTARY INFORMATION: Controlled substance Drug code Schedule Methylphenidate ............... Hydromorphone ................ Hydrocodone .................... Oripavine .......................... Thebaine ........................... Tapentadol ........................ 1724 9150 9193 9330 9333 9780 II II II II II II E:\FR\FM\02NON1.SGM 02NON1

Agencies

[Federal Register Volume 83, Number 213 (Friday, November 2, 2018)]
[Notices]
[Pages 55204-55205]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-23989]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical Technology Enterprise Consortium

    Notice is hereby given that, on October 12, 2018, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Medical Technology 
Enterprise Consortium (``MTEC'') has filed written notifications 
simultaneously with the Attorney General and the Federal Trade 
Commission disclosing changes in its membership. The notifications were 
filed for the purpose of extending the Act's provisions limiting the 
recovery of antitrust plaintiffs to actual damages under specified 
circumstances.
    Specifically, 8i Labs, Inc., Los Angeles, CA; Adaptive Phage 
Therapeutics, Inc. (Aphage), Gaithersburg, MD; Aleo BME, Inc., State 
College, PA; American Defense International (ADI), Washington, DC; 
Aptima, Inc., Woburn, MA; Atlantic Diving Supply, Inc. (ADS), Virginia 
Beach, VA; Benchmark Electronics, Inc., Scottsdale, AZ; BioMojo LLC, 
Cary, NC; BioSpyder Technologies, Inc., Carlsbad, CA; Brain Mapping 
Foundation, West Hollywood, CA; Brain Power, LLC, Cambridge, MA; 
BrainScope Company, Inc., Bethesda, MD; CAE Healthcare, Inc., Sarasota, 
FL; Carmell Therapeutics Corporation, Pittsburgh, PA; Case Western 
Reserve University, Cleveland, OH; Cell Guidance Systems Ltd.,

[[Page 55205]]

Cambridge, UK; Clear Scientific, LLC, Cambridge, MA; Cornerstone 
Government Affairs, Inc., Washington, DC; DePuy Synthes Products, Inc., 
Raynham, MA; Dignitas Technologies, Orlando, FL; ECM Therapeutics, 
Inc., Warrendale, PA; ElMindA Ltd., Herzliya, Israel; Family Health 
International DBA FHI 360, Durham, NC; Hypatia Project, Reston, VA; 
Institutes for Behavior Resources, Inc. (IBR), Baltimore, MD; 
Integrated MicroSciences, LLC, Frederick, MD; J. Craig Venter Institute 
(JCVI), Rockville, MD; KaloCyte, Inc., St. Louis, MO; Lieber Institute, 
Inc., Baltimore, MD; NanoDirect, LLC, Baltimore, MD; OXYVITA, Inc., 
Middletown, NY; Parsons Government Services, Inc., Pasadena, CA; 
Protocentral, Inc., Woburn, MA; Q2Pharma, Haifa, Israel; RAIN 
Scientific, Inc., Asheville, NC; Rehat, LLC, Pittsburgh, PA; Research 
Foundation for Mental Hygiene, Inc. (NYSPI), New York, NY; Responde2 
Corporation, Mountain View, CA; Saint Barnabas Medical Center (SBMC), 
Livingston, NJ; San Diego Blood Bank, San Diego, CA; SmartMD Systems, 
Inc., Manchester Center, VT; Sonica LLC, Evanston, IL; Spire, San 
Francisco, CA; Syracuse University, Syracuse, NY; The Charles Stark 
Draper Laboratory, Inc. (Draper), Cambridge, MA; The University of 
Arizona, Defense and Security Research Institute (DSRI), Tucson, AZ; 
Trauma Insight, LLC, San Antonio, TX; Trustees of Boston University, 
Boston, MA; University of Central Florida Research Foundation, Inc., 
Orlando, FL; University of Houston--Cullen College of Engineering, 
Houston, TX; Vivonics, Inc., Bedford, MA; and Washington State 
University, Pullman, WA; have been added as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MTEC intends to file additional 
written notifications disclosing all changes in membership.
    On May 9, 2014, MTEC filed its original notification pursuant to 
Section 6(a) of the Act. The Department of Justice published a notice 
in the Federal Register pursuant to Section 6(b) of the Act on June 9, 
2014 (79 FR 32999).
    The last notification was filed with the Department on May 3, 2018. 
A notice was published in the Federal Register pursuant to Section 6(b) 
of the Act on June 19, 2018 (83 FR 28448).

Suzanne Morris,
Chief, Premerger and Division Statistics Unit Antitrust Division.
[FR Doc. 2018-23989 Filed 11-1-18; 8:45 am]
 BILLING CODE 4410-11-P